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The μ-opioid receptor (MOPr) is a clinically important G protein-coupled receptor that couples to Gi/o proteins
and arrestins. At present, the receptor conformational changes that occur following agonist binding and
activation are poorly understood. This study has employed molecular dynamics simulations to investigate the
binding mode and receptor conformational changes induced by structurally similar opioid ligands of widely
differing intrinsic agonist efficacy, norbuprenorphine, buprenorphine, and diprenorphine. Bioluminescence
resonance energy transfer assays for Gi activation and arrestin-3 recruitment in human embryonic kidney 293
cells confirmed that norbuprenorphine is a high efficacy agonist, buprenorphine a low efficacy agonist, and
diprenorphine an antagonist at the MOPr. Molecular dynamics simulations revealed that these ligands adopt
distinct binding poses and engage different subsets of residues, despite sharing a common morphinan
scaffold. Notably, norbuprenorphine interacted with sodium ion-coordinating residues W2936.48 and
N1503.35, whilst buprenorphine and diprenorphine did not. Principal component analysis of the movements
of the receptor transmembrane domains showed that the buprenorphine-bound receptor occupied a distinct
set of conformations to the norbuprenorphine-bound receptor. Addition of an allosteric sodium ion caused the
receptor and ligand to adopt an inactive conformation. The differences in ligand–residue interactions and
receptor conformations observed here may underlie the differing efficacies for cellular signalling outputs for
these ligands.© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The μ-opioid receptor (MOPr) is a Gi/o coupled
receptor from the class A G protein-coupled receptor
(GPCR) family. It is responsible for both the analgesic
and euphoric effects of many opioid drugs [1] and is
therefore a protein of very significant clinical and
societal importance.
The process of GPCR activation, and particularly
the molecular difference between high and low
efficacy agonists, is poorly understood. The current
consensus is that ligand binding induces changes in
residue orientation around the ligand binding pocket,
termed micro-switches, that translate to larger rear-
rangements of the intracellular regions of the receptor,
hence promoting engagement with intracellular sig-Authors. Published by Elsevier Ltd. This
nses/by/4.0/).nalling partners such asG proteins and arrestins [2,3].
Onewell-established hallmark of receptor activation is
the outward movement of the lower part of transmem-
brane domain (TM) 6 and the concurrent small inward
shifts of TM5 and TM7, thus opening an intracellular
cavity in the receptor into which G protein or arrestin
can bind [4–9].
Residues forming a conserved network of polar
interactions allosterically connecting the ligand bind-
ing site and the intracellular face of MOPr [9–11] also
include those that comprise an allosteric sodium ion
binding site [12]. Sodium has been previously
described as a negative allosteric modulator of
MOPr and other class A GPCRs [13–18], and a
high-resolution X-ray crystal structure of the δ-opioid
receptor bound to an antagonist revealed a sodiumis an open access article under the CC BY license (http://
J Mol Biol (2017) 429, 1840–1851
1841Drug Binding and Efficacy in the μ Opioid Receptorion coordinated by conserved residues below the
ligand binding pocket [19]. These residues have been
proposed to be involved in signal transmission from
the ligand binding pocket to the G protein binding site
[11,20–23]. However, there is limited understanding of
the precise nature of this signal transmission through
the protein and hence the molecular nature of agonist
efficacy.
The MOPr ligands norbuprenorphine, buprenor-
phine, and diprenorphine share the same morphinan
scaffold (Fig. 1a), and all exhibit affinities for MOPr in
the nanomolar range [24,25] yet display fundamental
differences in intrinsic efficacy. Norbuprenorphine, a
metabolite of buprenorphine [26], is a full agonist at
MOPr, able to activate G proteins and recruit
arrestin-3, whilst buprenorphine is a MOPr partial
agonist, producing a submaximal activation of G
protein, and is unable to induce measurable
arrestin-3 recruitment to the receptor [27]. Diprenor-
phine is a MOPr antagonist [24], that is, it has
extremely low or zero efficacy. In this study, we first
confirmed the signalling characteristics of these
ligands using bioluminescence resonance energy
transfer (BRET) assays. Then, these structurally
related ligands were used in molecular dynamics
(MD) simulations of MOPr to explore ligand bindingFig. 1. Structurally similar ligands were used in MD simulatio
in this study, sharing the same morphinan scaffold. Carbons 1–
norbuprenorphine (yellow), and embedded in a cholesterol an
(red), developed from the antagonist-bound crystal structure [poses, residue interactions, andMOPr conformations,
which may confer the different abilities of these
ligands to engage intracellular signalling partners.Results
Agonist-induced G protein activation and
arrestin-3 recruitment
Human embryonic kidney 293 (HEK 293) cells
expressing HA-tagged rat MOPr, Gαi-renilla luciferase
(Rluc) II, and Gβγ-green fluorescent protein (GFP)
were used to detect dissociation of the Gα and Gβγ
subunits upon activation. A decrease in the BRET ratio
compared to cells treated with media or 0.01% DMSO
alone indicated dissociation, or rearrangement, of
these subunits [28]. HEK 293 cells expressing rat
MOPr-yellow fluorescent protein (YFP) and arrestin-
3-Rluc were used to detect ligand-induced recruitment
of arrestin-3 to MOPr. An increase in this BRET ratio
indicates arrestin-3 and MOPr coming into closer
proximity [29]. Concentration-response curves for Gi
activation and arrestin-3 recruitment by the MOPr
ligands compared to the standard full agonist DAMGOns bound to MOPr. (a) Structures of the MOPr ligands used
7 are labelled. (b) Model of MOPr (cyan) bound to a ligand,
d phospholipid bilayer (grey) solvated in water and NaCl
31].
Fig. 2. MOPr ligand concentration-response curves from BRET assays. Data obtained by BRET assay in HEK 293 cells
(see Materials and Methods) for (a) Gi activation and (b) arrestin-3 recruitment to MOPr. Values are mean ± SEM for 3–6
independent experiments.
1842 Drug Binding and Efficacy in the μ Opioid Receptorare shown in Fig. 2. EC50 and maximum response
values for eachagonist are listed in Table 1.Compared
to DAMGO, norbuprenorphine was a full agonist for Gi
activation (Fig. 2a) and a potent partial agonist for
arrestin-3 recruitment (Fig. 2b), producing approxi-
mately 70% of the maximum DAMGO response
(Table 1). Norbuprenorphine displayed approximately
10-fold higher potency than DAMGO in the arrestin-3
recruitment and a similar potency as DAMGO for Gi
activation (Table 1). Buprenorphine was aweak partial
agonist for Gi activation, producing less than 50% of
the maximum response achieved by DAMGO
(Fig. 2a). Buprenorphine produced very little response
in the arrestin-3 recruitment assay (Fig. 2b). A high
concentration (1 μM) of diprenorphine did not produce
a response in the Gi activation (Fig. 2a) or arrestin-3
recruitment assays (Fig. 2b). Incubation of cells with
1 μM diprenorphine for 10 min prior to the addition of
10 μM DAMGO completely inhibited the DAMGO
response for both Gi activation and arrestin-3 recruit-Table 1. EC50 and maximum response values for MOPr ligan
Ligand Gi activation
EC50 ± SEM (nM) Emax (relative to DA
DAMGO 42.9 ± 16.9 1.0 ± 0.07
Norbuprenorphine 110 ± 44.9 1.23 ± 0.12
Buprenorphine 283 ± 232 0.43 ± 0.08
Data aremean ± SEM for 4–6 independent experiments. Maximum res
recruitment assay for buprenorphine was approximately 100 nM.ment (Fig. 2), confirming that diprenorphine is a MOPr
antagonist, with extremely low or zero efficacy.
Ligand binding poses and residue interactions
Both conventional MD (cMD) and accelerated MD
(aMD) simulations were conducted with murine
MOPr (Fig. S6) embedded in a phospholipid and
cholesterol bilayer as described in Materials and
Methods (Fig. 1b) and bound to norbuprenorphine,
buprenorphine, or diprenorphine. aMD is a method
of increasing sampling over a short computational
time by employing a boost potential to accelerate
conformational changes [30]. Moreover, 8 repeats
of 125-ns long simulations were performed
(with different initial velocities) for each ligand–
receptor pair with each method, giving a total of
6 μs of trajectory data. The structure of antagonist
β-funaltrexamine (β-FNA) bound to MOPr was used
as a template to decide the initial orientation of theseds in the BRET assay in HEK 293 cells
Arrestin-3 recruitment
MGO) EC50 ± SEM (nM) Emax (relative to DAMGO)
1980 ± 473 1.0 ± 0.06
184 ± 64.5 0.69 ± 0.05
– * 0.10 ± 0.03
ponse is expressed relative to DAMGO. * EC50 value in the arrestin
Fig. 3. Ligands have different binding poses. Overlay of
the average binding poses of MOPr ligands from 1 μs of
accelerated MD simulations. Buprenorphine (blue) and
diprenorphine (yellow) adopt a position higher in the
binding pocket than norbuprenorphine (green).
1843Drug Binding and Efficacy in the μ Opioid Receptorligands [31]. Figures 3 and S1 show the average
binding poses after 1 μs of aMD. Despite sharing a
common morphinan scaffold and being docked into
the same initial binding position, norbuprenorphine
adopted a different binding pose to buprenorphine
and diprenorphine within the ligand binding pocket.
The amine–D1473.32 hydrogen bond is essential for
opioid binding [32] (superscript numbers follow the
Ballesteros–Weinstein numbering system for GPCR
residues [33]). Ligands pivoted about this interac-
tion, with norbuprenorphine favouring a position
lower (i.e., closer to the intracellular side) in the
binding pocket compared to the lower efficacy
ligands (Fig. 4). The presence of the cyclopropyl-
methyl group (Fig. 1a) restricted the ability of
buprenorphine and diprenorphine to pivot about the
amine–D1473.32 interaction; therefore, these ligands
favoured a position higher (i.e., nearer to the
extracellular side) in the binding pocket. These
binding poses were consistent across both 1 μs of
cMD and 1 μs of aMD; RMSD plots comparing each
ligand to its average binding position show that none
of the ligands deviated from the presented average
binding pose by more than 1 Å (Fig. S3), and theseFig. 4. Conformation of the W2936.48 toggle switch. Repr
receptor, (b) buprenorphine-bound receptor, and (c) diprenorph
for opioid binding D1473.32, and the different conformations ofaverage binding positions were similar between the
aMD and cMD simulations (Fig. S4).
Distances between the heavy atoms of the bound
ligand and the residues comprising the binding pocket
(Fig. S2) were recorded over the 1-μs simulation time.
Residues within 4 Å of each ligand, measured from
the average structures, are compared in Table 2,
whilst Fig. S5 shows the percentage of simulation time
that each residue is within this 4-Å cut-off distance.
The MOPr ligands shared some residue interactions;
for instance, all three ligands were in contact with
D1473.32 for at least 80%of the simulation time in both
cMD and aMD (Fig. S5) and interacted with H2976.52;
both residues are known to be essential for opioid
ligand binding [32,34]. In both the aMD and cMD
simulations, buprenorphine and diprenorphine were
able to interact with K2335.39, V2365.42, V3006.55, and
W3187.35, due to their location higher in the binding
pocket, whilst norbuprenorphine adopted a position
further away from these side chains. Similarly,
buprenorphine makes contact with Q1242.60 and
I1443.29 due to the carbon-7 side chain (refer to
Fig. 1a), whilst diprenorphine lacks this carbon-7
group, and norbuprenorphine sits too low in the
receptor binding pocket. Overall, buprenorphine
participated in a greater number of ligand–residue
interactions in both the aMD and cMD simulations
than norbuprenorphine or diprenorphine, which may
contribute to the slow dissociation rate of this ligand,
compared to norbuprenorphine and diprenorphine
[35]. These ligand–residue interactions are similar for
both aMD and cMD simulations (Table 2). Differences
between the two techniques likely reflect the en-
hanced sampling by aMD and do not affect the overall
interpretation.
It is noteworthy that the high efficacy agonist
norbuprenorphine interacted with W2936.48 and
N1503.35, both residues that form part of the
allosteric sodium ion pocket below the binding site,
whilst the low efficacy agonist and the antagonist did
not. Closer inspection of the simulation trajectories
revealed that this is due to a small rotation of TM3,
causing the N1503.35 side chain to fall out of the 4-Å
range for buprenorphine and diprenorphineesentative snapshots of (a) the norbuprenorphine-bound
ine-bound receptor. Showing the ligand, essential residue
the conserved W2936.48 rotamer toggle switch.
Table 2. Ligand–residue interactions
Accelerated MD
Q
124 
I144 
D
147 
Y
148 
N
150 
M
151 
K
233 
V
236 
W
293 
I296 
H
297 
V
300 
W
318 
I322 
G
325 
Y
326 
Norbuprenorphine
Buprenorphine
Diprenorphine
Conventional MD
Q
124 
I144 
D
147 
Y
148 
N
150 
M
151 
K
233 
V
236 
W
293 
I296 
H
297 
V
300 
W
318 
I322 
G
325 
Y
326 
Norbuprenorphine
Buprenorphine
Diprenorphine
(a)
(b)
Residues within 4 Å of the bound ligand, measured from the average structure of 1-μs simulation data in each case.
(a) Accelerated MD; (b) conventional MD.
1844 Drug Binding and Efficacy in the μ Opioid Receptorinteraction, whilst W2936.48 undergoes significant
changes in the angle of its side chain (Fig. 4). These
rotamer changes can be monitored by plotting the χ2
angle, as shown for the cMD simulation in Fig. 5.Fig. 5. Rotamer angle of W2936.48 with each ligand bo
norbuprenorphine bound, W2936.48 favours a horizontal confo
average (solid lines).With norbuprenorphine bound, the indole ring of
W2936.48 favours a “horizontal” conformation, par-
allel to the lipid bilayer, maintaining a χ2 angle of 0–
60°, and spanning the base of the ligand binding site.und, during 1 μs of conventional MD simulations. With
rmation. Each dataset is plotted as raw data and a running
1845Drug Binding and Efficacy in the μ Opioid ReceptorThis orientation obstructs the allosteric sodium ion
site (Figs. 4a and 5). With buprenorphine (Figs. 4b
and 5) or diprenorphine bound (Figs. 4c and 5), the
side chain of W2936.48 adopts a “vertical” confor-
mation, with the indole ring of the tryptophan
perpendicular to the bilayer, favouring a χ2 angle
between 80 and 120° and pointing into the ligand
binding pocket. Both buprenorphine- and
diprenorphine-bound receptors occasionally sample
the “horizontal” conformation of W2936.48, with
buprenorphine more frequently than diprenorphine
(Fig. 5).
Principal component analysis shows distinct
helical arrangements
Large, high-dimensional datasets, such as that
obtained by MD, are difficult to analyse by eye or
simple statistics. Principal component (PC) analysis
(PCA) is a method of reducing highly dimensional data
to the main “principal components”, which account for
the most variation [36]. PCA was used in this study to
plot subtle changes in receptor conformation and allow
the mapping of clusters of conformations explored by
the different receptor–ligand complexes. After aligning
all trajectories to a set of “core residues” that showed
the leastmovement over the simulation time (Fig. S6a),
PCA was performed on the three-dimensional
Cartesian coordinates of the alpha carbons of the
receptor TMs (Fig. S6b) to avoid variations being
masked by the highly dynamic extracellular and
intracellular loops and side-chain movements. The
receptor conformation at each time point was projected
onto PCs 1 and 2, producing clusters of receptor
conformations that converge if thehelical structuresareFig. 6. Principal component analysis shows distinct receptor
each time point onto principal components 1 and 2 (see Materia
MD simulations. The norbuprenorphine-bound receptor is
diprenorphine-bound receptor in yellow. The conformation of tbecoming more similar or diverge if the conformations
are different. For the cMD simulations, PCs 1 and 2
account for 28.2% and 11.3% of the variance,
respectively. For the aMD, PCs 1 and 2 account for
14.2% and 9.7% of the variance. In both the aMD
(Fig. 6a) and cMD (Fig. 6b), the norbuprenorphine-
bound MOPr and buprenorphine-bound MOPr form
distinct clusters. This indicates different helical arrange-
ments depending on the bound ligand. An overlay of
structures extracted from the norbuprenorphine-bound
cluster and the buprenorphine-bound cluster is shown
in Fig. S7. There are multiple shifts in the positions of
several of the transmembrane helices, notably the
movement of the extracellular ends of TM1, 2 and 3,
and the intracellular end of TM5. The diprenorphine-
bound MOPr cluster overlaps somewhat with the
buprenorphine-bound cluster, suggesting that the
buprenorphine-bound receptor favours a more inactive
conformation compared with the norbuprenorphine-
bound receptor. The greater spread of the aMD PCA
plot (Fig. 6a) shows that the conformational space
sampled by aMD is greater than that by the cMD
simulations (Fig. 6b), highlighting the value of this
technique in increasing sampling over relatively short
computational time. Nevertheless, both approaches
gave the same overall result.
Effect of an allosteric sodium ion on ligand
binding pose and W2936.48 conformation
During unliganded MOPr simulations, a sodium ion
was observed to move from the extracellular space
into the receptor pore to occupy the allosteric sodium
site (data not shown). The coordinates of this sodium
ion were used to set up two repeats of 125-ns cMD–ligand clusters. Projection of the receptor conformation at
ls and Methods). (a) Accelerated MD and (b) conventional
in green, buprenorphine-bound receptor in blue, and
he crystallised β-FNA-bound receptor is projected in red.
Fig. 7. An allosteric sodium ion
alters the binding pose of norbupre-
norphine. Representative snapshots
of the (a) norbuprenorphine-bound
receptor and (b) buprenorphine-
bound receptor in the presence or
absence of an allosteric sodium ion
(purple). In the absence of sodium,
norbuprenorphine adopts a position
deeper in the binding pocket with
W2936.48 in the horizontal position
(green). In the presence of sodium,
norbuprenorphine shifts upwards in
the binding pocket, and theW2936.48
side chain points upwards (dark grey). The binding pose of buprenorphine and the preferred angle of theW2936.48 side chain
in the absence (blue) and presence (yellow) of sodium do not differ.
1846 Drug Binding and Efficacy in the μ Opioid Receptorand aMD simulations of MOPr bound to norbuprenor-
phine or buprenorphine in the presence of anallosteric
sodium ion, giving a total of 1 μs of trajectory data.
Ligand binding poses and the conformation of the
W2936.48 rotamer in the presence and absence of an
allosteric sodium ion are shown in Fig. 7. These
conformations were consistent between cMD and
aMD simulations. The sodium ion did not leave the
allosteric site during the simulation time for either cMD
or aMD for either ligand. In the norbuprenorphine-
bound simulations (Fig. 7a), the presence of a sodium
ion caused the ligand to shift upwards in the binding
pocket to occupy a position similar to buprenorphine
and diprenorphine. The rotamer ofW2936.48 switched
from a horizontal conformation to the vertical
conformation favoured by the buprenorphine- andFig. 8. Principal component analysis in the absence and pre
conformation at each time point onto principal components 1 a
(b) conventional MD simulations. The norbuprenorphine-bound
and buprenorphine-bound receptor in the absence of sodiu
presence of sodium is in black, and the buprenorphine-bounddiprenorphine-bound receptor, pointing into the ligand
binding pocket. In the buprenorphine-bound simula-
tions (Fig. 7b), the presence of a sodium ion did not
induce significant change in the ligand binding pose or
the W2936.48 rotamer. The χ2 angle for W2936.48 in
the presence or absence of sodium for each ligand
boundsimulation is plotted inFig. S8. In thepresenceof
sodium, the W2936.48 χ2 angle of norbuprenorphine-
bound MOPr is maintained at around 80–120°,
comparable to the buprenorphine-bound MOPr in
both the presence and absence of sodium. RMSD
plots indicate that these ligand binding poses in the
presence of an allosteric sodium were stable for the
entirety of the simulation time (Fig. S9).
PCA was performed on the receptor TMs as
described above. With the sodium ion present, bothsence of an allosteric sodium ion. Projection of the receptor
nd 2 (see Materials and Methods). (a) Accelerated MD and
receptor in the absence of an allosteric sodium is in green
m in blue. The norbuprenorphine-bound receptor in the
receptor in the presence of sodium is in yellow.
1847Drug Binding and Efficacy in the μ Opioid Receptorthe buprenorphine and norbuprenorphine clusters
overlap with the sodium-free buprenorphine-bound
cluster (Fig. 8) and the diprenorphine-bound cluster
(Fig. 6). This is consistent for both aMD (Fig. 8a) and
cMD simulations (Fig. 8b). Taken together, these
PCA plots and the change in ligand binding pose and
rotamer of W2936.48 suggest that the presence of an
allosteric sodium ion causes the norbuprenorphine-
bound MOPr to favour an inactive conformation,
whilst the buprenorphine-bound MOPr is relatively
unchanged.Discussion
The results from the BRET assay confirm previous
studies characterising norbuprenorphine as a high
efficacy agonist capable of recruiting arrestin-3 to
MOPr, buprenorphine as a low efficacy agonist with
minimal or no arrestin recruitment to the receptor,
and diprenorphine as an antagonist for G protein
activation and arrestin-3 recruitment, with very low or
zero efficacy [24,27]. Based on some previous
studies [27], buprenorphine would be expected to
have higher potency in the G protein activation
assay; however, higher than expected EC50 values
for buprenorphine in signalling assays have been
reported by others [37]. When compared to the
balanced agonist DAMGO, norbuprenorphine ap-
pears to display a degree of arrestin bias in these
assays. McPherson et al. [27] did not report
norbuprenorphine exhibiting significant bias be-
tween GTPγS binding and arrestin PathHunter
assays. This discrepancy may be due to the different
assay systems used or that norbuprenorphine could
be an arrestin-biased agonist and will be the subject
of further investigation.
Both cMD and aMD simulations revealed that
these structurally similar ligands adopted distinct
binding positions in the ligand binding pocket. The
simulated binding poses were maintained over the
entire simulation time. Each 125-ns repeat simula-
tion was started from a newly minimised structure
and the dynamics initialised with new random
velocities and the standard heating protocol. Fur-
thermore, the ligand binding poses for each ligand
were similar between repeats of cMD and aMD
simulations, giving confidence that the sampling was
adequate and the differences in poses seen for the
different ligands may be relevant to the physiological
situation. Recently reported MD simulations of the β2
adrenoceptor revealed ligand–protein interaction
fingerprints for a variety of different ligands that
correlated with the drug efficacy and the size of the
intracellular G protein binding cavity, although the
binding positions of the ligands were not greatly
different [38].
The presence of a cyclopropylmethyl group on the
amine confers a degree of antagonist activity inMOPr ligands [18,39,40]. In our simulations, this
shared N substituent in buprenorphine and dipre-
norphine appeared to reduce the ability of the ligand
to pivot about the amine–D1473.32 interaction so that
these low efficacy ligands sat higher in the binding
pocket and did not interact with residues in the
sodium ion allosteric site and conserved polar
network. Using MD simulations of the agonist-
bound MOPr, Huang et al. [6] have shown that the
binding pose of the antagonist BU74 is unstable
when the cyclopropylmethyl group was docked into
the polar cavity at the base of the binding site and
shifts upwards in the binding pocket, suggesting that
this ring group cannot stably interact with residues in
this polar cavity and in agreement with the data we
present here.
The residue W2936.48 has previously been iden-
tified as a rotamer toggle switch for GPCR activation
in the conserved polar network and participating in
coordination of a sodium ion [6,41–45]. The MD
simulations described here showed that the full
agonist norbuprenorphine came into close contact
with this residue, affecting the preferred rotamer of
the W2936.48 side chain, whereas the low efficacy
agonist buprenorphine and antagonist diprenorphine
did not. This provides an explanation for the differing
efficacies of these ligands. Norbuprenorphine is able
to activate this rotamer toggle switch, thus disrupting
the allosteric sodium site and allowing MOPr to
adopt an active conformation. Buprenorphine and
diprenorphine are less able to alter the W2936.48
rotamer, so MOPr is less likely to adopt an active
conformation. Both the MOPr crystallised with
agonist BU72 and the recently described G protein-
biased agonist PZM21 also appear to interact
with W2936.48 [6,46]. Moreover, MD simulations
of MOPr bound to BU72 or another agonist
β-fuoxymorphamine show changes in the W2936.48
rotamer, suggesting that interaction with this residue
is a common mechanism amongst small molecule
MOPr agonists [6]. However, these MD simulations
with BU72 show the opposite conformation of the
W2936.48 rotamer to that described here, whilst the
χ2 angle of this residue in MD simulations with
hydromorphone or morphine bound was different
again [47]. This alternative behaviour of W2936.48 in
the presence of different ligands indicates that
receptor activation involves a complex mechanism
to give rise to the different helix conformations
observed in the present study and cannot be simply
explained by a single key residue.
Buprenorphine is a low efficacy agonist [24,25] but
is able to activate MOPr, albeit producing a lower
maximum response than higher efficacy agonists.
The MD simulations reported here showed buprenor-
phine adopting an overlapping binding pose, partially
overlying PCA clusters, and a similar W2936.48
rotamer to the antagonist diprenorphine. This poses
the question of how buprenorphine activates MOPr;
1848 Drug Binding and Efficacy in the μ Opioid Receptorone possibility is that buprenorphine is sometimes
able to engage the W2936.48 toggle switch but with
lower probability than the high efficacy agonist
norbuprenorphine. Indeed, during these MD simula-
tions, buprenorphine did infrequently alter its binding
position to overlap with the norbuprenorphine binding
pose, with a corresponding change in W2936 .48
rotamer (Fig. 5). Another possibility is that buprenor-
phine is capable of activating MOPr via an alternative
mechanism than the W2936.48 rotamer. An NMR
study of MOPr in the presence and absence of BU72
showed initial agonist-induced conformational changes
in helix 8 and intracellular loop 1 preceding the larger
movements of TM5 and TM6 [7], although the
mechanism of ligand-induced changes in helix 8 and
intracellular loop 1 is not yet known. Recently, an MD
study comparing MOPr bound to morphine and the G
protein-biased ligand TRV-130 revealed alternative
allosteric transduction mechanisms between the
ligand binding pocket and intracellular G protein
binding site for these two drugs [48]. It is possible
that buprenorphine can also produce receptor activa-
tion via a different mechanism. The PCA plots show
the buprenorphine-bound MOPr occupying confor-
mations distinct from both the norbuprenorphine- and
diprenorphine-bound receptors (Fig. 6). This may
represent a different active conformation stabilised by
buprenorphine.
If norbuprenorphine-bound MOPr favours an active
conformation, we would predict that the presence of
the negative allosteric modulator, sodium, would
disrupt this conformation. Indeed, we found that whilst
an allosteric sodium ion did not significantly alter the
binding pose, W2936.48 rotamer, and PCA clustering
of the buprenorphine-bound MOPr, the presence of a
sodium ion did disrupt the norbuprenorphine-bound
MOPr, causing it to occupy a more inactive confor-
mation. Other MD studies that started with a sodium
ion occupying the allosteric site of the active-like
adenosine A2A receptor have observed either the
sodium leaving the binding pocket or the sodium ion
remaining bound and the GPCR adopting an inactive
conformation whilst agonist binding is destabilised
[49]. Here, the sodium ion did not leave the receptor
pore, but the bound ligand andMOPr adopted inactive
conformations. This perhaps reflects the relatively
short simulation time and that the simulations were
started from an already inactive receptor structure,
therefore favouring retention of the sodium ion in the
allosteric pocket and destabilisation of the agonist
binding pocket.
We propose that the distinct receptor conformations
captured by the PCA reflect the differing ligand
efficacies at the MOPr. Although the BRET experi-
ments suggested that norbuprenorphine may display
some bias towards arrestin recruitment, this is yet to
be validated in further experiments, and so, the ability
to discriminate between an active MOPr conformation
and an arrestin-biased conformation by MD simula-tions is yet to be achieved. In order to characterise
receptor conformations that favour G protein or
arrestin signalling, a larger set of structurally diverse
test compounds, some displaying a strong bias for G
protein or arrestin signalling, would be required.
In conclusion, this study has identified molecular
differences between structurally related MOPr li-
gands that correlate with their different intrinsic
agonist efficacies. MD simulations showed the high
efficacy agonist norbuprenorphine favouring an
alternative position in the binding pocket to the low
efficacy agonist buprenorphine and the antagonist
diprenorphine, without the overlap of the morphinan
scaffold. This different pose allowed norbuprenor-
phine to interact with the W2936.48 toggle switch,
important for GPCR activation and part of the
allosteric sodium site. Importantly, the MOPr TMs
occupy distinct sets of conformations with a different
ligand bound. Together, these results suggest that
small changes in the ligand binding pose and ligand–
residue interactions lead to global conformational
changes in the MOPr helices and induce different
receptor conformations. These alternative helical
conformations identified in this MD study may confer
different abilities of MOPr to activate intracellular
signalling partners.Materials and Methods
Cell culture and transfection
HEK 293 cells were cultured at 37 °C in Dulbecco's
modified Eagle'smedium (DMEM) supplementedwith
10% foetal bovine serum and penicillin/streptomycin.
Cells were seeded onto 10-cm dishes and grown to
80% confluence before transfection. Cells were
transfected with a 1:1 ratio of rat MOPr conjugated
to YFP and arrestin tagged with Rluc or with a 1:1:1
ratio of HA-tagged rat MOPr, Gαi-RlucII, and
Gβγ-GFP, 24 h before assay, using jetPEI DNA
transfection reagent (Polyplus).
BRET assay
Immediately prior to assay, cells were resuspended
in clear DMEM and then transferred to a 96-well plate
at 90 μl per well. DAMGO, buprenorphine, and
norbuprenorphine dissolved in water; diprenorphine
dissolved in DMSO; and coelenterazine h and
coelenterazine 400a dissolved in methanol were
diluted in DMEMmedia to the required concentration.
The final DMSO concentration for diprenorphine and
controls was 0.01%. The BRET assay was performed
on the FLUOstar Omega microplate reader. Drugs
and coelenterazine were added at time 0, and the
luminescence was measured over 2 min (G protein
activation) or 10 min (arrestin recruitment). The ratio
1849Drug Binding and Efficacy in the μ Opioid Receptorof the light emitted by YFP or GFP to the light emitted
by Rluc was used to calculate the BRET ratio. To
determine whether diprenorphine can antagonise the
DAMGO response, we incubated the cells with 1 μM
diprenorphine for 10 min, prior to the addition of
10 μM DAMGO, and the assay was performed as
described above. All treatments were performed in
duplicate, and the average response was taken. The
assay was repeated in 3–6 independent experiments.
Data were expressed as the percentage increase
(arrestin recruitment) or decrease (G protein activation)
in the BRET ratio from control cells treated with media
or media +0.01% DMSO, and analyses and curve
fitting were performed inGraphPadPrism version 7. All
ligands were compared to DAMGO as the standard
high efficacy agonist at MOPr.
System preparation for MD
The X-ray crystal structure of antagonist-bound
MOPr (PDB: 4DKL) [31] was obtained from the
Protein Data Bank and prepared in Insight II. Ligands
and the T4 lysozyme were removed, and a loop
search was performed to find a homologous loop to
model in the missing intracellular loop 3. A loop was
selected by visual inspection and the residues
changed to the correct mouse MOPr sequence
(Fig. S6). The side chains were inspected for clashes
and bonds rotated where necessary. The receptor
was embedded in a POPC:POPE:cholesterol lipid
bilayer at a 5:5:1 ratio using the replacement
method, and the simulation box (initial dimensions:
90, 110, 90 Å) solvated with TIP3P water and 0.15 M
NaCl using the CHARMM-GUI software [50]. The
antagonist β-FNA shares a morphinan scaffold with
buprenorphine, norbuprenorphine, and diprenor-
phine. The binding pose of β-FNA in the crystal
structure was used as a template to determine the
initial orientation of the ligands for MD simulation.
Ligands were parameterised using Antechamber
and the general Amber force field [51]. All ligands
were protonated at the amine to allow interaction
with D1473.32. Amber parameter topology and
coordinate files were prepared in LEaP.
MD simulations and analysis
Structures wereminimised over 10,000 steps; then,
the system was heated under constant volume and
pressure with lipids restrained, from 0 K to 100 K over
5 ps, and then from 100 K to 310 K over 100 ps. We
performed 10 rounds of 500-ps equilibration under
constant pressure to equilibrate the periodic box
dimensions. Each simulation was run for 125 ns
under the Amber ff14SB and Lipid14 force fields
[52,53]. Temperature and pressure were controlled
using the Langevin thermostat and the anisotropic
Berendsen barostat, with a 2-fs time step and
trajectories written every 100 ps. Simulations wererun for a total of 1 μs for each receptor–ligand complex
in a series of 8 × 125 ns parallel steps, with newly
minimised structures and new random velocities for
each simulation, under both cMD and aMD [30]. aMD
uses an external boost potential to accelerate
conformational changes, allowing for increased sam-
pling over the same amount of computational time as
cMD. This technique allows protein conformational
changes to be investigated, which would otherwise
not be accessible over the short computing time
available. Parameters for the aMD were calculated as
described in Kappel et al. [54]. Trajectories were
visualised in VMD, and the analysis was performed
using cpptraj [55]. Trajectories were aligned to a set of
“core” residues that showed the least amount of
movement across the simulations (Fig. S6a) to avoid
including general translation and rotationof the protein
in the analysis, before RMSD and PCA calculations
were performed. The covariance matrix was calculat-
ed and diagonalised using cpptraj, and the PCs were
obtained bymapping the three-dimensional Cartesian
coordinates of the alpha carbons of the TMs of all
trajectories (Fig. S6b). Each frame of the simulated
trajectories was mapped onto PC1 and PC2 to
produce a plot visualising the conformational space
occupied by the receptor at each time point. Images of
ligand binding poses and side-chain orientations were
prepared in Chimera [56].
Simulations with an allosteric sodium ion
Simulations were also performed with MOPr in the
absence of any ligand. During these unliganded
simulations, a sodium ion was observed to enter the
receptor pore from the extracellular space and occupy
theallosteric sodiumsite (data not shown). Theposition
of this sodium ion was in agreement with the published
high-resolution structure of the antagonist-bound
δ-opioid receptor [19]. The coordinates of this allosteric
sodium ion in the unliganded simulation were used to
place a sodium ion into the receptor pore of MOPr
bound to buprenorphine or norbuprenorphine. Two
independent 125ns simulations were run, as described
above, for each ligand, under both aMD and cMD
simulations, giving a total of 500 nsof trajectory data for
each ligand–sodium complex.Acknowledgements
This work was supported by a Biotechnology and
Biological Sciences Research Council (BBSRC)
studentship awarded to K.J.S. under the South
West Biosciences (SWBio) DTP scheme (Grant
BB/J014400/1), and carried out using the computa-
tional facilities of the Advanced Computing
1850 Drug Binding and Efficacy in the μ Opioid ReceptorResearch Centre, University of Bristol – http://www.
bris.ac.uk/acrc/. We thank Dr. Michel Bouvier,
University of Montreal, for the gift of the G protein
BRET constructs (NB Domain Therapeutics is the
holder of the license for all commercial use of the
constructs), and Dr. Nick Holliday, University of
Nottingham, for the arrestin-3 BRET construct.Appendix A. Supplementary Data
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2017.05.009.
Received 11 January 2017;
Received in revised form 7 May 2017;
Accepted 8 May 2017
Available online 11 May 2017
Keywords:
G protein-coupled receptor;
μ-opioid receptor;
molecular dynamics;
buprenorphine
Abbreviations used:
MOPr, μ-opioid receptor; GPCR, G protein-coupled
receptor; TM, transmembrane domain; BRET,
bioluminescence resonance energy transfer; MD,molecular
dynamics; HEK 293, human embryonic kidney 293; Rluc,
renilla luciferase; GFP, green fluorescent protein; YFP,
yellow fluorescent protein; cMD, conventional MD; aMD,
accelerated MD; β-FNA, β-funaltrexamine; PC, principal
component; PCA, principal component analysis; DMEM,
Dulbecco's modified Eagle's medium.References
[1] H.W. Matthes, R. Maldonado, F. Simonin, O. Valverde, S.
Slowe, I. Kitchen, et al., Loss of morphine-induced analgesia,
reward effect and withdrawal symptoms in mice lacking the
μ-opioid-receptor gene, Nature 383 (1996) 819–823.
[2] D. Zhang, Q. Zhao, B. Wu, Structural studies of G protein-
coupled receptors, Mol. Cells 38 (2015) 836–842.
[3] V. Katritch, V. Cherezov, R.C. Stevens, Structure-function of
the G-protein-coupled receptor superfamily, Annu. Rev.
Pharmacol. 53 (2013) 531–556.
[4] J.A.R. Dalton, I. Lans, J. Giraldo, Quantifying conformational
changes in GPCRs: glimpse of a common functional
mechanism, BMC Bioinformatics 16 (2015) 124.
[5] P. Huang, J. Li, C. Chen, I. Visiers, H. Weinstein, L.Y. Liu-
Chen, Functional role of a conserved motif in TM6 of the rat μ
opioid receptor: constitutively active and inactive receptors
result from substitutions of Thr6.34(279) with Lys and Asp,
Biochemistry 40 (2001) 13,501–13,509.
[6] W. Huang, A. Manglik, A.J. Venkatakrishnan, T. Laeremans,
E.N. Feinberg, A.L. Sanborn, et al., Structural insights into
μ-opioid receptor activation, Nature 524 (2015) 315–321.[7] R. Sounier, C. Mas, J. Steyaert, T. Laeremans, A. Manglik, W.
Huang, et al., Propagation of conformational changes during
μ -opioid receptor activation, Nature 524 (2015) 375–378.
[8] Y. Kang, X.E. Zhou, X. Gao, Y. He, W. Liu, A. Ishchenko,
et al., Crystal structure of rhodopsin bound to arrestin by
femtosecond X-ray laser, Nature 523 (2015) 561–567.
[9] B.G. Tehan, A. Bortolato, F.E. Blaney, M.P. Weir, J.S.
Mason, Unifying family A GPCR theories of activation,
Pharmacol. Ther. 143 (2014) 51–60.
[10] R.O. Dror, D.H. Arlow, P. Maragakis, T.J. Mildorf, A.C. Pan, H.
Xu, et al., Activation mechanism of the β2-adrenergic receptor,
Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 18,684–18,689.
[11] D. Wootten, C.A. Reynolds, C. Koole, K.J. Smith, J.C.
Mobarec, J. Simms, et al., A hydrogen-bonded polar network
in the core of the glucagon-like peptide-1 receptor is a
fulcrum for biased agonism: lessons from class B crystal
structures, Mol. Pharmacol. 89 (2016) 335–347.
[12] W. Liu, E. Chun, A.A. Thompson, P. Chubukov, F. Xu, V.
Katritch, et al., Structural basis for allosteric regulation of
GPCRs by sodium ions, Science 337 (2012) 232–236.
[13] D.E. Selley, C.C. Cao, Q. Liu, S.R. Childers, Effects of
sodium on agonist efficacy for G-protein activation in μ-opioid
receptor-transfected CHO cells and rat thalamus, Br. J.
Pharmacol. 130 (2000) 987–996.
[14] V. Katritch, G. Fenalti, E.E. Abola, B.L. Roth, V. Cherezov,
R.C. Stevens, Allosteric sodium in class A GPCR signaling,
Trends Biochem. Sci. 39 (2014) 233–244.
[15] Y. Miao, A.D. Caliman, J.A. McCammon, Allosteric effects of
sodium ion binding on activation of the M3 muscarinic G-
protein-coupled receptor, Biophys. J. 108 (2015) 1796–1806.
[16] Y. Shang, V. LeRouzic, S. Schneider, P. Bisignano, G.W.
Pasternak, M. Filizola, Mechanistic insights into the allosteric
modulation of opioid receptors by sodium ions, Biochemistry
53 (2014) 5140–5149.
[17] C.B. Pert, S.H. Snyder, Opiate receptor binding of agonists
and antagonists affected differentially by sodium, Mol.
Pharmacol. 10 (1974) 868–879.
[18] S. Yuan, H. Vogel, S. Filipek, The role of water and sodium
ions in the activation of the μ -opioid receptor, Angew. Chem.
Int. Ed. Engl. 52 (2013) 10,112–10,115.
[19] G. Fenalti, P.M. Giguere, V. Katritch, X.P. Huang, A.A.
Thompson, V. Cherezov, et al., Molecular control of δ-opioid
receptor signalling, Nature 506 (2014) 191–196.
[20] A. Massink, H. Gutierrez-de-Teran, E.B. Lenselink, N.V. Ortiz
Zacarias, L. Xia, L.H. Heitman, et al., Sodium ion binding
pocket mutations and adenosine A2A receptor function, Mol.
Pharmacol. 87 (2015) 305–313.
[21] K.E. Livingston, J.R. Traynor, Disruption of the Na+ ion
binding site as a mechanism for positive allosteric modulation
of the μ-opioid receptor, Proc. Natl. Acad. Sci. U. S. A. 111
(2014) 18,369–18,374.
[22] L.A. Stoddart, B. Kellam,S.J. Briddon, S.J. Hill, Effect of a toggle
switch mutation in TM6 of the human adenosine A(3) receptor
onGi protein-dependent signalling andGi-independent receptor
internalization, Br. J. Pharmacol. 171 (2014) 3827–3844.
[23] H. Zhang, H. Unal, R. Desnoyer, G.W. Han, N. Patel, V.
Katritch, et al., Structural basis for ligand recognition and
functional selectivity at angiotensin receptor, J. Biol. Chem.
290 (2015) 29,127–29,139.
[24] L. Toll, I.P. Berzetei-Gurske, W.E. Polgar, S.R. Brandt, I.D.
Adapa, L. Rodriguez, et al., Standard binding and functional
assays related to medications development division testing
for potential cocaine and opiate narcotic treatment medica-
tions, NIDA Res. Monogr. 178 (1998) 440–466.
1851Drug Binding and Efficacy in the μ Opioid Receptor[25] P. Huang, G.B. Kehner, A. Cowan, L.Y. Liu-Chen, Compar-
ison of pharmacological activities of buprenorphine and
norbuprenorphine:norbuprenorphine is a potent opioid ago-
nist, J. Pharmacol. Exp. Ther. 297 (2001) 688–695.
[26] E.J. Cone, C.W. Gorodetzky, D. Yousefnejad, W.F.
Buchwald, R.E. Johnson, The metabolism and excretion of
buprenorphine in humans, Drug Metab. Dispos. 12 (1984)
577–581.
[27] J. McPherson, G. Rivero, M. Baptist, J. Llorente, S. Al-Sabah,
C. Krasel, et al., μ-opioid receptors: correlation of agonist
efficacy for signalling with ability to activate internalization,
Mol. Pharmacol. 78 (2010) 756–766.
[28] C. Denis, A. Saulière, S. Galandrin, J.M. Sénard, C. Galés,
Probing heterotrimeric G protein activation: applications to
biased ligands, Curr. Pharm. Des. 18 (2012) 128–144.
[29] P. Molinari, I. Casella, T. Costa, Functional complementation
of high-efficiency resonance energy transfer: a new tool for
the study of protein binding interactions in living cells,
Biochem. J. 409 (2008) 251–261.
[30] L.C. Pierce, R. Salomon-Ferrer, C. Augusto F de Oliveira,
J.A. McCammon, R.C. Walker, Routine access to millisecond
time scale events with accelerated molecular dynamics,
J. Chem. Theory Comput. 8 (2012) 2997–3002.
[31] A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, J.M.
Mathiesen, R.K. Sunahara, et al., Crystal structure of the
μ-opioid receptor bound to a morphinan antagonist, Nature
485 (2012) 321–326.
[32] X. Cui, A. Yeliseev, R. Liu, Ligand interaction, binding site
and G protein activation of the μ opioid receptor, Eur. J.
Pharmacol. 702 (2013) 309–315.
[33] J.A. Ballesteros, H. Weinstein, Integrated methods for the
construction of three-dimensional models and computational
probing of structure-function relations in G protein-coupled
receptors, Methods Neurosci. 25 (1995) 366–428.
[34] T. Kaserer, A. Lantero, H. Schmidhammer, M. Spetea, D.
Schuster, μ opioid receptor: novel antagonists and structural
modeling, Sci. Rep. 6 (2016) 21,548.
[35] M.S. Virk, S. Arttamangkul, W.T. Birdsong, J.T. Williams,
Buprenorphine is a weak partial agonist that inhibits opioid
receptor desensitization, J. Neurosci. 29 (2009) 7341–7348.
[36] A. Amadei, A.B. Linssen, H.J. Berendsen, Essential dynamics
of proteins, Proteins 17 (1993) 412–425.
[37] A. Knapman, M. Santiago, M. Connor, A6V polymorphism of
the human μ-opioid receptor decreases signalling of mor-
phine and endogenous opioids in vitro, Br. J. Pharmacol. 172
(2015) 2258–2272.
[38] H.C.S. Chan, S. Filipek, S. Yuan, The principles of ligand
specificity on β2-adrenergic receptor, Sci. Rep. 6 (2016) 34,736.
[39] J. Shim, A. Coop, A.D. MacKerell Jr., Consensus 3Dmodel of
μ-opioid receptor ligand efficacy based on a quantitative
conformationally sampled pharmacophore, J. Phys. Chem. B
115 (2011) 7487–7496.
[40] J. Shim, A. Coop, A.D. MacKerell Jr., Molecular details of the
activation of the μ opioid receptor, J. Phys. Chem.B 117 (2013)
7907–7917.
[41] R. Singh, D.P. Hurst, J. Barnett-Norris, D.L. Lynch, P.H.
Reggio, F. Guarnieri, Activation of the cannabinoid CB1
receptor may involve a W6.48/F3.36 rotamer toggle switch,
J. Pept. Res. 60 (2002) 357–370.[42] S.D. McAllister, G. Rizvi, S. Anavi-Goffer, D.P. Hurst, J.
Barnett-Norris, D.L. Lynch, et al., An aromatic microdomain at
the cannabinoid CB1 receptor constitutes an agonist/inverse
agonist binding region, J. Med. Chem. 46 (2003) 5139–5152.
[43] J. Wess, S. Nanavati, Z. Vogel, R. Maggio, Functional role of
proline and tryptophan residues highly conserved among G
protein-coupled receptors studied by mutational analysis of
the M3 muscarinic receptor, EMBO J. 12 (1993) 331–338.
[44] B. Holst, R. Nygaard, L. Valentin-Hansen, A. Bach, M.S.
Engelstoft, P.S. Petersen, et al., A conserved aromatic
lock for the tryptophan rotameric switch in TM-VI of seven-
transmembrane receptors, J. Biol. Chem. 285 (2010)
3973–3985.
[45] L. Valentin-Hansen, T.M. Frimurer, J. Mokrosinski, N.D.
Holliday, T.W. Schwartz, Biased Gs versus Gq proteins and
β-arrestin signaling in the NK1 receptor determined by
interactions in the water hydrogen bond network, J. Biol.
Chem. 290 (2015) 24,495–24,508.
[46] A. Manglik, H. Lin, D.K. Aryal, J.D. McCorvy, D. Dengler, G.
Corder, et al., Structure-based discovery of opioid analgesics
with reduced side effects, Nature 537 (2016) 185–190.
[47] X. Cong, P. Campomanes, A. Kless, I. Schapitz, M.
Wagener, T. Koch, et al., Structural determinants for the
binding of morphinan agonists to the μ-opioid receptor, PLoS
One 10 (2015) e0135998.
[48] S. Schneider, D. Provasi, M. Filizola, How oliceridine (TRV-
130) binds and stabilizes a μ-opioid receptor conformational
state that selectively triggers G protein-signaling pathways,
Biochemistry 55 (2016) 6456–6466.
[49] H. Gutierrez-de-Teran, A. Massink, D. Rodriguez, W. Liu,
G.W. Han, J.S. Joseph, et al., The role of a sodium ion
binding site in the allosteric modulation of the a(2A)
adenosine G protein-coupled receptor, Structure 21 (2013)
2175–2185.
[50] S. Jo, T. Kim, V.G. Iyer, W. Im, CHARMM-GUI: a web-based
graphical user interface for CHARMM, J. Comput. Chem. 29
(2008) 1859–1865.
[51] J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollamn, D.A. Case,
Development and testing of a general Amber force field,
J. Comput. Chem. 25 (2004) 1157–1174.
[52] J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E.
Hauser, C. Simmerling, ff14SB: improving the accuracy of
protein side chain and backbone parameters from ff99SB,
J. Chem. Theory Comput. 11 (2015) 3696–3713.
[53] C.J. Dickson, B.D. Madej, A.A. Skjevik, R.M. Betz, K. Teigen,
I.R. Gould, et al., Lipid14: the Amber lipid force field, J. Chem.
Theory Comput. 10 (2014) 865–879.
[54] K. Kappel, Y. Miao, J.A. McCammon, Accelerated molecular
dynamics simulations of ligand binding to a muscarinic G-
protein-coupled receptor,Q.Rev. Biophys. 48 (2015) 479–487.
[55] D.R. Roe, T.E. Cheatham III, PTRAJ and CPPTRAJ: software
for processing and analysis of molecular dynamics trajectory
data, J. Chem. Theory Comput. 9 (2013) 3084–3095.
[56] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M.
Greenblatt, E.C. Meng, et al., UCSF chimera—a visualization
system for exploratory research and analysis, J. Comput.
Chem. 25 (2004) 1605–1612.
